NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
Recruiting now · Phase 1
Conditions studied: Locally Advanced Rectal Cancer (LARC)
In brief
The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.
Key facts
- Study ID
- NCT06459869
- Run by
- Akamis Bio
- People needed
- 30
- Starts
- 2025-04-07
- Expected to finish
- 2028-12-30
- Last updated by the study team
- 2026-06-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (enrolling)
- AdventHealth Orlando — Orlando, Florida, United States (enrolling)
- Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
- The Royal Marsden NHS Foundation Trust — Sutton, United Kingdom (enrolling)
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- University College London NHS FT — London, United Kingdom (enrolling)
- University of Southern California — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.